Eyestem Research Profile
Key Indicators
- Authorised Capital ₹ 9.80 M
as on 30-12-2024
- Paid Up Capital ₹ 2.38 M
as on 30-12-2024
- Company Age 9 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 47.53%
(FY 2022)
- Profit -82.40%
(FY 2022)
- Ebitda -101.99%
(FY 2022)
- Net Worth 0.87%
(FY 2022)
- Total Assets 3.87%
(FY 2022)
About Eyestem Research
The Company is engaged in the Research & Development Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 9.80 M and a paid-up capital of Rs 2.38 M, as per Ministry of Corporate Affairs (MCA) records.
Jogin Desai, Suresh Ramu, Ramesh Byrapaneni, and Six other members serve as directors at the Company.
- CIN/LLPIN
U74999KA2015PTC164505
- Company No.
084306
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 Aug 2015
- Date of AGM
28 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Eyestem Research?
Board Members(9)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Suresh Ramu  | Director | 07-Nov-2017 | Current |
| Subramanian Ramaswamy | Director | 13-Jan-2020 | Current |
| Jogin Desai | Director | 25-Aug-2015 | Current |
Gerardus Hoogland  | Director | 07-Sep-2020 | Current |
Dhruv Sareen  | Director | 01-Aug-2016 | Current |
Ashok Vohra  | Director | 07-Nov-2017 | Current |
Financial Performance of Eyestem Research.
Eyestem Research Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 47.53% increase. The company also saw a substantial fall in profitability, with a 82.4% decrease in profit. The company's net worth moved up by a moderate rise of 0.87%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Eyestem Research?
In 2022, Eyestem Research had a promoter holding of 6.46% and a public holding of 93.54%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Nkure Therapeutics Private LimitedActive 2 years 11 monthsAshok Vohra and Mahendra Rao are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Eyestem Research?
Eyestem Research has a workforce of 1 employees as of Mar 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Eyestem Research, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Eyestem Research's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
